Fight against cancer an enduring investment motivation in September quarter despite markets
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives...
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society...
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX) has fielded more promising results from its PTX-100 T Cell...
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke tells Proactive the company has been granted additional Orphan Drug Designation...
Prescient Therapeutics Ltd (ASX:PTX) is trading higher on being granted additional Orphan Drug Designation for PTX-100 for...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.